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Summary: 
Chronic liver diseases in children represent a rising problem with significant effects on public health. In fact, 
several pediatric liver diseases are precursors of adult chronic hepatopathies, cirrhosis and hepatocellular 
carcinoma. The prevalence of liver diseases in children is unknown. In the USA, every year, 15,000 children 
are hospitalized for liver diseases, but these disorders continue to be under-recognized or diagnosed late. The 
main reason is due to the frequent absence of symptoms in the vast majority of liver diseases, especially in 
the early stages. In the last few decades several advances have been made in understanding the pathogenesis 
of liver diseases, permitting the discovery of new therapeutic targets to treat liver diseases, thus improving 
the natural history of these disorders. In this article we discuss the most recent advances in the understanding 
of the pathogenesis, diagnosis and treatment of the most frequent pediatric liver diseases. 
 
 
Introduction  
Chronic hepatobiliary diseases represent a relatively rare disorder in children. However, the burden of 
chronic hepatopathies, defined as impact of liver disease on the global health, including its frequency, its 
effects on longevity, morbidity, quality of life and finance, with direct health care expenditures and indirect 
costs, is very important.  
The exact prevalence of pediatric liver diseases is unknown.  Liver disease is not cited in the first 15 causes 
of death in children; the only data available reported that each year approximately 15.000 pediatric patients 
are hospitalized for liver diseases in USA [1]. European epidemiological pediatric data are not available so 
far; for adulthood, it is reported that 29 million people are affected by liver diseases and that cirrhosis and 
end-stage liver diseases are responsible for around 170.000 deaths every year, representing the 12
th
 most 
common cause of death [2]. Globally, the number of annual liver cancer and cirrhosis death rose in 2010, 
with 33 per cent more than in 1990 [3], according to the first-ever World Health Organization (WHO) study 
of liver disease mortality. 
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Pediatric hepatopathies are particularly important because of several pediatric diseases are precursor of adult 
chronic liver diseases, cirrhosis and hepatocellular carcinoma; therefore, treatment and prevention in 
pediatric setting would be highly cost-effective. Based on these data, governments are now considering liver 
diseases as a public health priority with urgent need to develop non-invasive tests to screen for early stage of 
fibrosis in order to promptly treat and stopping or slowing the progression of liver damage.  
Instead, liver diseases in children are often under-recognized or late diagnosed. This under-diagnosis is 
mainly due to the frequent absence of symptoms in the vast majority of liver diseases, especially in the early 
stages. Moreover, different liver diseases often show a  similar pattern of presentation. In fact, generally, 
hepatic cells react to different injuries with similar responses, with frequently monomorphic clinical and 
laboratory signs. The types of liver injury are generally divided into two patterns: cholestatic or 
hepatocellular damage, with sometimes overlap pattern. Moreover, the causes of liver diseases in children 
are manifold, and many of these are rare disorders. It is important to remember in the diagnostic work-up of 
suspected hepatopathy in children that many liver diseases are associated with specific age groups, such as – 
for example - biliary atresia in the first months of life or Wilson disease after 3-5 years of age (see Table 1). 
Again, in the difficult diagnosis of liver disease it is important to consider the frequent absence of symptoms, 
with only sometimes non-specific signs, such as fatigue, loss of appetite, vague abdominal pain, 
hepatomegaly or pruritus (Table 2). Although many advances have been made in the diagnostic tools for 
pediatric liver disease (laboratory assessment, specific imaging techniques), percutaneous liver biopsy 
remains the standard procedure to obtain liver tissue for histopathological evaluation and a valuable tool in 
the diagnosis, prognosis and management of many liver diseases. Recently, the Hepatology Committee of 
European Society of Gastroenterology, Hepatology And Nutrition (ESPGHAN) has published a position 
paper on liver biopsy, focusing on indication, contraindications and type of procedure in principal pediatric 
hepatopathies [4].   
Many advances have been made in the knowledge of pathogenesis of many liver diseases and based on these 
discoveries novel emerging treatments have been proposed, changing the natural history and epidemiology 
of disorders. Moreover, the advances in transplant procedure have opened new possibilities for providing 
care for several hepathopathies, previously only partially treatable.  
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In this manuscript, we discuss the most recent advances in knowledge of pathogenesis, histological features, 
diagnosis and treatment of principal pediatric chronic liver diseases.   
 
NAFLD 
Non-alcoholic fatty liver disease (NAFLD) represents the leading cause of chronic liver disease in children, 
as a direct consequence of the worldwide epidemic obesity in children. The exact prevalence of 
NAFLD/NASH is unknown, but the available data reported that approximately 3-10% of general pediatric 
population is affected by NAFLD and this percentage increases up to 70% in morbidly obese children [5]. 
The histopathological scenario of NAFLD ranges from simple triglycerides accumulation in the hepatocytes 
to more advanced forms, characterized by various degrees of inflammation and fibrosis (non-alcoholic 
steatohepatitis – NASH).  
In the last decade, many advances have been made in the knowledge of pathogenetic mechanisms involved 
in NAFLD/NASH and several intriguing novel therapeutic approaches have been proposed. The known 
theory of "two hits hypothesis", in which the accumulation of liver fat (first hit) increased the vulnerability of 
liver cells to "second hits", such as insulin resistance and oxidative stress, causing the disease progression, 
has been now exceeded. Current evidence suggests the central role of “lipotoxicity”, respect to simple 
triglycerides accumulation, in inducing the hepatocytes dysfunction leading to the progression of liver injury 
to NASH [6]. Some studies have, in fact, demonstrated that triglycerides accumulation in the hepatocytes, 
due to increased synthesis or reduced export of lipids, is unable, by itself, to determine the progression of 
liver damage. Probably, triglycerides accumulation occurs in parallel with the generation of these lipotoxic 
metabolites, which act as reactive oxygen species (ROS), triggering necroinflammation changes typical of 
NASH [6]. Insulin-resistance and inflammatory cytokines disarray are closely involved in this pathogenetic 
mechanism, inducing a variety of intra- and inter-cellular signaling cascades leading to fibrosis and advanced 
liver damage [6]. Moreover, an interesting interaction between liver and gut has been proposed as important 
in the pathogenesis of chronic hepatitis, such as NAFLD. Recent studies have demonstrated that NAFLD is 
associated with increased intestinal permeability (IP) and small intestinal bacterial overgrowth (SIBO), and 
that these factors are associated with the severity of hepatic disease [7].  Based on these novel findings, 
actually NAFLD is considered a “multi-hits” parallel disorder, in which genetic, epigenetic and 
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environmental factors strictly interact causing the onset and progression of liver injury [6,9]. In addition, 
recent studies have highlighted the importance of genetic factors in the development of NAFLD/NASH, 
identifying single nucleotide polymorphisms (SNPs) in specific genes involved in lipid metabolism (Lipin 1 
- LPIN1, patatin-like phospholipase domain containing-3 - PNPLA3), oxidative stress (superoxide dismutase 
2 – SOD2), insulin signalling (insulin receptor substrate-1 – IRS-1) and fibrogenesis (Kruppel-like factor 6 - 
KLF6), which confer a genetic predispositions to more severe forms of liver damage [9,10].  Recently, a 
non-invasive kit to screen for four-polymorphisms related to NASH has been proposed to recognize children 
at high risk of disease progression, but further and larger studies are needed before implementing the use of 
such genetic tests in clinical practice on large scale [11].  
NAFLD is generally asymptomatic and the diagnosis is made after the evidence of hyperechogenic liver at 
ultrasound or in case of abnormal levels of liver enzymes. To make the diagnosis of NAFLD other causes of 
hepatic steatosis (viral hepatitis, autoimmune hepatitis, Wilson's disease, α1-anti-trypsin, celiac disease) in 
children should be ruled out by appropriate tests. According to recent recommendation of Hepatology 
Committee of ESPGHAN, NAFLD should be suspected in all overweight or obese children and adolescents 
with increased waist circumference aged over 3 years, especially if there is a NAFLD history in relatives 
[12]. The first diagnostic step in these children should be abdominal ultrasound and liver function tests, 
followed by the exclusion of other liver diseases [12]. To date, liver biopsy remains the “imperfect gold 
standard” for diagnosis, and it is the only diagnostic tool to distinguish between NASH and simple steatosis, 
and to determine the severity of liver damage [12]. Several non-invasive biomarkers, both laboratory that 
imaging tools, of NAFLD/NASH have been proposed in the last years [13] . Oxidative stress markers, 
inflammatory cytokines and adipokines have been tested as potential non-invasive indices of fibrosis both in 
adults than children, but none of these tests have proved totally satisfactory [13]. Actually, these markers 
need further validation and are confined to research purposes because of their costs and limited availability. 
Identifying and validating potential novel non-invasive biomarkers of NAFLD and NASH is a central area of 
research in the near future. Regarding imaging techniques, hepatic ultrasonography remains the most 
commonly used modality because of safe, non-invasive, less expensive and user-friendly. However, 
ultrasound is unable to detect fat infiltration below 30% or to assess disease severity or the presence or 
absence of NASH. Hepatic magnetic resonance (MRI) has a number of advantages, including operator 
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independence and reproducibility. Unfortunately, similarly to ultrasound, MRI cannot distinguish NASH 
from simple steatosis nor detect the presence of fibrosis and, moreover, its high costs and need of sedation, 
especially in younger children, limit significantly its use. Transient elastography (TE) is a novel 
ultrasonographic technique, which employs ultrasound-based technology to measure liver stiffness (LSM), 
and has been validated for use mainly in adult patients with chronic hepatitis C and chronic hepatitis B. 
However, recent studies had shown good results in adults with NAFLD [13]. The main limitations of TE are 
represented by its inaccuracy in obese subjects and by the limited data currently available for pediatric 
NAFLD patients. Further validation of TE is necessary before it can be routinely adopted for the evaluation 
of NAFLD in childhood [14,15]. Novel therapeutic strategies have been tested in the last years with 
interesting results [16]. The drugs initially used in treatment of NAFLD, such as anti-oxidants (vitamin E), 
insulin-sensitizing (metformin) and cytoprotective agents (ursodeoxycholic acid – UDCA) have given 
disappointing results, with only limited effects, and, therefore, to date there is no definitive treatment for 
pediatric NAFLD. Regarding vitamin E, the largest adult RCT, the PIVENS trial, showed significant 
improvements in the aminotransferase levels, hepatic steatosis and lobular inflammation in the vitamin E 
group compared to the placebo group [17]. In 2012, the American Association for the Study of Liver 
Diseases (AASLD) suggested the use of vitamin E (800 UI/daily) in adult non-diabetic patients with biopsy-
proven NASH [18]. In pediatric setting, in the TONIC trial, the largest pediatric RCT, significant differences 
between the vitamin E and placebo groups in improving alanine aminotransferase (ALT) levels were not 
found; however, an improvement in hepatocytes ballooning, without differences in steatosis or lobular 
inflammation, was observed between the two groups ([19]. To date, the available data for vitamin E are not 
convincing enough to recommend the use of this drug in pediatric NAFLD [20]. Larger well-designed RCTs 
with adequate power and duration concentrating on the histological endpoints in children are still needed to 
better define the efficacy of vitamin E in pediatric NAFLD[20]. Interesting data have been instead reported 
in children for omega-3 fatty acid, mainly for docosaesaenoic acid (DHA), with beneficial effect on 
metabolic parameters (insulin-sensitivity and triglycerides level) and on liver steatosis, at echographic and 
histological examination[21-24]. Recently, Janczyk and coworkers reported the results of their multicenter, 
double-blind, placebo-controlled, RCT in which 76 pediatric patients with NAFLD received weight-based 
omega-3 fatty acids (DHA and EPA in 3:2 proportion, 450-1300 mg daily) or placebo twice daily for 24 
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weeks. In this study, supplementation with omega-3 fatty acids was not superior to placebo in inducing 
significant reduction in ALT levels or in improving hepatic steatosis on ultrasonography [25]. Therefore, 
future larger studies for longer duration with histological end-points are required to prove the efficacy of 
omega-3 on NAFLD in children.  
Bariatric surgery represents a new frontier of the treatment of morbid obesity with co-morbidities. In the 
recent years, the number of adolescents undergoing to bariatric surgery in America has increased fivefold 
with positive effect on metabolic parameters [26]. Recently, bariatric surgery is becoming a useful option in 
patients with NASH, also in adolescents. In 2015, the Hepatology Committee of ESPGHAN has proposed a 
position paper about the inclusion criteria for bariatric intervention in adolescents with morbid obesity [27]. 
Many studies have shown that bariatric surgery improved metabolic parameters and histologic features of 
NASH; in a recent metanalysis, Mummadi et al reported a high rate of improvement of histological features 
of NASH (90% for steatosis and 70% for fibrosis) after bariatric surgery [28]. However, despite these 
encouraging results, it should be highlighted that the paucity of long-term outcome information regarding 
nutritional deficiency, growth and developmental impact of bariatric surgery in children and adolescents 
makes the role of bariatric surgery in the pediatric patients still controversial [27,29]. Another useful 
alternative is represented by temporary devices for inducing weight loss, such as intragastric balloon, in 
which a significant weight loss could induce a positive effect on metabolic parameters related to metabolic 
syndrome and liver alteration [30] 
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Chronic viral hepatitis: the changes of epidemiology and the new drugs 
The epidemiology of viral hepatitis in children has radically changed in the last years, due to improved 
hygiene measures, health status and blood supply, and to introduction of universal vaccination for hepatitis 
B. Moreover, recently, new antiviral drugs have been introduced in the pharmacological armamentarium, 
mainly for hepatitis C, with encouraging results in adults and in pediatric pilot studies. The association 
between improved prevention strategies and new effective drugs could lead in the coming years to a 
significant reduction in the cases of chronic viral hepatitis and their medium and long-term complications 
(cirrhosis and hepatocellular carcinoma – HCC).  
Hepatitis B 
Despite the conspicuous reduction in prevalence of chronic hepatitis B infection observed in the last two 
decades, HBV hepatitis continues to represent a major global health problem [31]. It has been estimated that 
actually 2 billion people worldwide are affected by HBV infection and that about 600.000 persons died every 
year for hepatic consequences of chronic hepatitis B, such as cirrhosis and HCC [32].  
Since 1990, a comprehensive strategy was recommended in order to eliminate of HBV transmission in 
Industrialized Countries based on: 
- Universal vaccination of infants in the first months of life (according to local vaccination programs)  
- Routine screening for HBV of all pregnant women and immunoprophylaxis at birth to infants born 
by infected women 
- Routine vaccination of children/adolescents  
- Vaccination of adults at increased risk for infection (health-care workers, patients affected by 
chronic diseases, etc)   
Though this program in the last twenty years the prevalence of HBV infection is dramatically decreased and 
some previously high-prevalence countries (Hepatitis B surface antigen (HBsAg) positivity higher than 8%), 
such as China and Taiwan, have become at intermediate or low prevalence (HBsAg 2-7% or <2%, 
respectively) [33-37].  
Chronic hepatitis B (CHB) had generally a benign course in children, even if in one old cohort study has 
been reported that 3–5% and 0.01–0.03% of chronic carriers develop cirrhosis or hepatocellular carcinoma, 
respectively, before adulthood [38,39,40]. Considering the average life expectancy of pediatric patients, the 
risk for HCC rises to 9–24%, with an incidence of cirrhosis of 2–3% per year during lifetime [41][42].  
The natural history of chronic hepatitis B in children is generally favorable; the vast majority of children are 
asymptomatic with normal growth and psychological development. Three phases of chronic hepatitis B have 
been described: the immune-tolerant state, typical of pediatric age, characterized by high viral replication, 
positive HBeAg, and normal levels of aminotransferases; the immune active state, described by active 
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inflammation and elevated aminotransferases, which can progress into cirrhosis; the inactive carrier state, 
marked by seroconversion to anti-HBe and low viral replication with favorable long-term outcome [43].  
Differently from adults, clear guidelines for treatment of pediatric CHB are lacking and a panel of experts 
developed the available indication [44]. Treatment should be considered in children in immune active state; 
the presence of inflammation and fibrosis at liver biopsy (Ishak), not mandatory but suggested before 
treatment, and positive family history for HCC, are considered additional criteria for pharmacological 
treatment. The ideal objective of CHB treatment is to induce HBsAg clearance, reducing the risk of disease 
progression with improvement of long-term survival and quality of life [38]. When HBsAg seroclearance is 
not achieved, sustained off-therapy suppression of viral replication with subsequent reduction of 
inflammation and ALT levels, and/or durable anti-HBe seroconversion, are considered a good end-points, 
being associated with improved prognosis, including decreased risk of HCC [38]. The FDA has approved the 
use of five medications for treating hepatitis B in children: Interferon-alpha (IFN-α) and four nucleoside 
analogues (Lamivudine, Tenofovir, Entacavir, and Adefovir dipivoxil). IFN-α can be used in children older 
than 12 months of age, lamivudine starting at 3 years of age, adefovir and tenofovir in children aged 12 years 
and older and entecavir starting from 16 years of age. IFN-α has been the first drug used for treatment of 
CHB in children; the long-term studies have demonstrated that IFN-α accelerate HBeAg seroconversion, but 
treated and untreated patients had a similar rate of HBeAg clearance at long-term follow-up [44]. Licensing 
of highly effective nucleoside analogues (NA) for older children and adolescents has opened new 
possibilities of treatment. However, the risk of emergence of drug resistant strains represents a major long-
term issue for young patients. In this contex, promising data have been emerged in children for tenofovir, a 
NA with an excellent safety profile and absent drug resistance. Murray et al have demonstrated in 
adolescents (12-17 years) a virologic and biochemical response in 89% and 74% of treated patients, 
respectively [45]. Considering the good safety profiles and absence of emergence of drug resistance strain at 
72 weeks of therapy, tenofovir seems to be an interesting agent for children, even if long-term follow up 
studies are needed to confirm these data. Moreover, recent evidence reported the efficacy and security of 
tenofovir not only in children, but also in pregnancy, in an attempt to reduce a mother-to-infant HBV 
transmission. Two recent prospective multicenter trials demonstrated that the treatment with TDF for highly 
viremic mothers significantly decreased perinatal HBV transmission without side effects on obstetric and 
neonatal parameters [46,47].  
 
Hepatitis C 
Following the accurate screening of blood products and organ donors, the prevalence of HCV has been 
significantly reduced. Today, it is estimated that 170 million people worldwide are affected by chronic 
hepatitis C [48]. In children the main source of infection is the vertical transmission, mother to child, which 
occurs in about 5% of cases. The spontaneous clearance of the virus is observed in 20% of children infected 
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in the first 3 years of life, with rate of chronicity of infection in 80% of cases. Similarly to CHB, the 
principal risk related to HCV infection is the development of cirrhosis and its complication during life.  
The natural history of chronic hepatitis C (CHC) in children is usually benign, even if pediatric CHC is 
considered a slowly progressive disease with accumulating liver damage following the years [49]. By the end 
of adolescence, about 2% of patients develop cirrhosis [50].  
Assessment of liver disease severity is generally recommended prior to therapy in adults and children [51]. 
In adults, alternative non-invasive methods, such as liver stiffness measurement (LSM) and well-established 
panels of blood biomarkers, are routinely used instead of liver biopsy to assess liver disease severity prior to 
start therapy. Conversely, in children, these non-invasive tests are not commonly used in clinical practice; 
the actual European and American pediatric guidelines for the management of CHC in children suggest to 
forego pre-treatment liver biopsy in children with HCV genotypes 2 or 3 who have a high (>80%) 
probability of achieving a virological response with presently available treatments [49]. In the other 
genotypes (1 or 4), in which about 50% of virological response has been described, pre-treatment liver 
biopsy remains useful for decision making; if fibrosis is mild, expectant management (awaiting better 
regimens) is justifiable.  
The combined therapy (Pegylated (PEG)-interferon (IFN) plus ribavirin represents the standard treatment for 
children aged 3 years and older [52].  This regimen is effective in obtaining sustained viral rates in 55% of 
children chronically infected with genotype 1-4 and in 90% of genotypes 2-3. Recently, novel different 
direct-acting antiviral agents (DAAs) are emerged for treatment of chronic HCV infection in adults [53]. 
These agents block viral replication by directly inhibiting one of several steps of the HCV lifecycle. The 
DAAs include NS3-4A protease inhibitors, nucleoside analogue inhibitors of the HCV RNA-dependent RNA 
polymerase (RdRp) and NS5A, another protein inhibitors.  
The first used NS3-4A protease inhibitors were telaprevir and boceprevir. Their use in monotherapy resulted 
in initial decline in plasma HCV-RNA concentration with unfortunately rapid selection of resistant variants 
and viral breakthrough [54]. Better results in terms of sustained virological response (70-80% in genotype 1) 
and risk of resistance were reported for the association of telaprevir or boceprevir with PEG-IFN plus 
ribavirin [55]. An important limitation of this triple therapy is the important adverse effects, mainly 
hematological. Similarly to NS3-4A proteinase inhibitors, also NS5A inhibitors, as daclatasvir, showed a 
rapid reduction in viral load with frequent onset of resistance [56].  
NS5B inhibitors interfere with viral replication by binding to the NS5B RNA-dependent RNA polymerase. 
Sofosbuvir is the most promising drug of this class of DAAs [57]. The use of Sofosbuvir associated to 
Ribavirin in adults showed interesting results with optimal sustained virological response (70-90%) in 
genotype 2-3 and good safety profile. For previously untreated genotype 1 patients, sofosbuvir plus ribavirin 
resulted in 84% virological response [56][58]. These results, associated with its IFN-free regimen, the good 
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safety profiles and the once-daily administration, make sofosbuvir a suitable drug also in pediatric setting 
[59], but specific pediatric studies are needed.  
Wilson’s disease 
Wilson's disease (WD) is a genetic copper storage disorder, transmitted as an autosomal recessive trait, 
caused by mutation in ATP7B gene (13q), causing a progressive toxic accumulation of copper in the body 
[60]. 
WD is present worldwide with a frequency ranging from 1: 30.000 to 1: 50.000, depending on the different 
ethnic groups evaluated. It is estimated that 1:90 people is a carrier of the disease. Regional clustering of WD 
has been identified as in an Italian region, Sardinia, in which the prevalence is higher, about 1:2700 [61]. 
Wilson’s disease is an important liver disorder in which a prompt diagnosis and initiation of therapy could 
significantly change the natural history of the disorder and the quality of life for the patients. In fact, if early 
and adequately treated, WD has a good quality of life and a favorable outcome. If WD is not recognized, the 
progression of hepatic and neurologic damage can be very rapid and end stage liver disease can occur with 
need of liver transplantation [62].  
In 2003, Ferenci et al.  proposed a diagnostic score for WD in children including clinical, biochemical, 
histological and molecular parameters [63]. The first step in the diagnostic work-up for WD is represented by 
serum ceruloplasmin levels, which are characteristically reduced in WD. However, it is known that in 20% 
of pediatric and adult patients with WD ceruloplasmin levels may be normal. Furthermore, on the other hand, 
low levels of ceruloplasmin could be observed also in other hepatic disorder, such as decompensated liver 
disease or in other chronic hepatopathies, as congenital disorder of glycosylation [60][64].  
Recently, relative exchangeable copper (REC) has been proposed and evaluated as a new faster diagnostic 
test for WD. REC corresponds to the labile fraction of copper bond mainly to albumin. An increased REC 
reflects a blood and tissue copper overload that occurs after saturation of hepatocytes. Further investigations 
are needed to verify the promising data about this diagnostic approach [65].  
Another useful diagnostic test is the basal urinary copper (CUB), which is related to the age at diagnosis and 
to the copper overload. Values > 100 g / 24 hours are diagnostic of WD, but several data have demonstrated 
that lower values should be considered diagnostic in pediatric setting, suggesting a new pediatric cut-off at > 
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40 g / 24 h. In addition other diagnostic test is measurements of urine excretion of copper after a challenge 
penicillin sheets (CuPCT), the values > 1600 g/24 h are considered diagnostic [66]. Hepatic copper 
accumulation is the histological mark of WD; liver copper content exceeding 250 g/g dry weight is 
diagnostic for WD. The other qualitative histological evaluation of hepatic copper is suggestive but not 
diagnostic of WD [67]. Genetic tests searching for mutations in ATP7B gene conclude the diagnostic process 
of WD. The presence of mutations on both chromosomes permits a definitive diagnosis of WD, while the 
absence of genetic mutations cannot exclude the diagnosis in the presence of clinical and laboratory signs 
[68]. To date, it has reported over 520 mutations in ATP7B gene in the Human Genome Mutation Database 
[69].  
Medical therapy is mandatory for the whole-life and arbitrary discontinuation is particularly worrisome, 
exposing to the risk of acute liver failure and death. Conventional medical treatment for children with WD is 
represented by copper chelators (penicillamine and trientine) and zinc. The chelating agents mobilize 
intracellular copper in circulation promoting the urinary excretion of copper, while zinc causes a reduced 
intestinal absorption of copper and simultaneously reduced the damaging effects of free copper in the 
hepatocytes. Recently it was reported that about 30% of WD patients adequately treated since childhood with 
the available drugs do not exhibit complete normalization of liver enzymes but have a good quality of life 
and a favorable outcome [70].  
The treatment of pediatric patients is quite different from adulthood. In children with mild liver disease and 
in asymptomatic children, monotherapy with zinc seems to be effective in to treatment of WD at the onset 
and during the course of the disease, as maintenance therapy. The children unresponsive to zinc or with more 
severe hepatic injury should be treated with chelators.  
In conclusion, the pharmacological available options for pediatric WD seem to be effective in the vast 
majority of cases. To date, the research is looking for novel therapeutic strategies for WD in addition to 
conventional therapy. The main field of interest is the identification of new molecular strategies able to 
restore the function of mutated protein, decreasing the toxic copper accumulation. 
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Autoimmune hepatitis 
Autoimmune hepatitis is a progressive inflammatory disorder of the liver, characterized by 
hypertransaminasemia, high level of immunoglobulin G (IgG) and by the presence of autoantibodies. The 
main histological feature is the interface hepatitis in the absence of a known etiology [71]. Based on 
autoantibodies pattern, two type of AIH have been described in children: type 1, with seropositivity for 
smooth muscle antibodies (SMA) and/or antinuclear antibodies (ANA), and type 2, with positivity for liver 
kidney microsomal type 1 antibodies (anti-LKM1) or for liver cytosol type 1 antibodies (anti-LC1) [72]. 
These two types differ for age at onset, type of presentation, response to treatment withdrawal.  
The prevalence of AIH varies between different areas, but generally it is about 2 cases per 200000 pediatric 
patients. Recent data showed an increase of the prevalence of this disease from 3% to 12% in the last decade 
in pediatric population [73]. AIH remains today an under-diagnosed disorder, and some decompensated liver 
cirrhosis due to ‘cryptogenic hepatitis’ are in reality secondary to autoimmune liver diseases [74]. The 
diagnosis of AIH is in fact based on the simultaneous combination of clinical, serological and histological 
features and not on a definite diagnostic test. Moreover, the clinical presentation of AIH are highly variable 
in children, ranging from an acute hepatitis (40% of cases) with the risk of progression to liver failure 
(especially in AIH type II), and an insidious onset (25-40% of cases), with progressive fatigue, intermittent 
jaundice, anorexia, and weight loss, lasting several months before diagnosis. In a minor group of patients, 
about 10%, AIH may begin with complications of advanced liver disease, such as portal hypertension, 
cirrhosis, hypersplenism [74][75]. Therefore, a high index of suspicion should be held, in order to prompt 
diagnose and treat AIH, reducing the risk to develop serious complications and end stage liver diseases. It 
has been demonstrated that the prognosis is related to the presence of cirrhosis at the initial liver biopsy; the 
presence of cirrhosis on initial liver biopsy has no impact on the overall survival rate, as well as on the 
survival free of liver transplantation [76]. 
The goal of immunosuppressive treatment is represented by the prevention of disease progression, 
maintaining on long term the lowest dosage of drugs, avoiding or reducing the need of liver transplantation. 
The standard therapy in children is represented by corticosteroids, which are effective in near 80% of cases, 
associated in the vast majority of cases to Azathioprine [77].  Cessation of treatment is considered if a liver 
D
ow
nl
oa
de
d 
by
 [A
nd
rea
 V
an
ia]
 at
 14
:36
 06
 D
ec
em
be
r 2
01
5 
biopsy shows minimal or no inflammatory changes after 1 year of normal liver function tests. However, it is 
advisable not to attempt to withdraw treatment within 2 years from diagnosis or during or immediately 
before puberty, when relapses are more common. Despite the efficacy of standard immunosuppressive 
treatment, severe hepatic decompensation may develop, even after many years of apparently good 
biochemical control, leading to transplantation 10–15 years after diagnosis in 10% of the patients. Inpatients 
(up to10%) in whom standard immunosuppression is unable to induce stable remission or who are intolerant 
to azathioprine, mycophenolatemofetil at a dose of  20mg/kg twice daily has been successfully used [78][79]. 
In case of persistent no response or of intolerance to mycophenolate mofetil, the use of calcineurin inhibitors 
(cyclosporin A or tacrolimus) should be considered [80][81]. New drugs, such as budenoside, are being 
evaluated for treatment of AIH in children with a reduction in steroid side-effects [82][83]. The available 
data seem to demonstrate that budesonide in association with azathioprine therapy was capable of 
maintaining remission with fewer side effects respect to prednisone [84,85]. However, budesonide may be 
less effective in inducing remission. To date, budesonide could be considered a valid alternative in selected 
non-cirrhotic patients who are at risk of adverse effects from steroids, but further larger studies are needed to 
define its efficacy in children with AIH [86]. 
A particular subtype of AIH is the seronegative form, in which none of the typical autoantibodies are 
detectable. In these cases the diagnosis can be more difficult and a high index of suspicion should be held. 
The correct diagnosis of this form is based on the combination of serological pattern (generally elevation of 
IgG), typical histological findings and appropriate investigations to carefully exclude other possible causes 
of liver disease. If promptly diagnosed and treated, these AIH subtypes respond positively to standard 
immunosuppressive therapy [87].   
 
Expert commentary 
Even if generally considered a rare disorder, chronic liver diseases in children represent a growing problem 
with important effects on public health. In fact, advances in the management of children with chronic liver 
disease have enabled many to survive into adulthood with or without their native livers, so that the most 
common of these conditions are becoming increasingly common in adult hepatology practice. Therefore, 
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creating a standardized transition program represents an important advance in modern medicine, but only 
poor information and suggestions are available for chronic liver disease. Moreover, the amelioration of 
management of pediatric chronic hepatopathies, with prompt diagnosis and effective therapy, could lead to a 
better health care status in adulthood. Treating pediatric patients offers the chance to prevent progressive 
liver injury, reducing or delaying the need of liver transplantation. Moreover, prevention programs, aiming 
for example to reduce alcohol intake or to counteract the epidemic obesity in pediatric setting, should reduce 
the incidence of alcoholic fatty liver disease (ASH) and NASH in adulthood. At the same time, research 
programs on pediatric hepatopathies should be strengthened, in order to permit significant advances, in terms 
of early diagnosis and effective treatment.    
 
Five year view 
In the last years, several advances have been made in the understanding of hepatobiliary physiology with 
development of more precise approaches to the diagnosis and management of liver disease in infants and 
children.  
These novel discoveries have deeply changed previous knowledge of chronic liver diseases, mainly in terms 
of pathophysiology and targeted therapies. As known, fibrosis represents the final response of the liver to 
chronic non-resolving injury. As previously stated, in the liver, fibrosis is mainly due to chronic hepatitis B 
and C, autoimmune and biliary disorders, metabolic diseases, and, increasingly, NASH. Differently from 
what is previously described, recent research has demonstrated that fibrosis is not a static phenomenon, but it 
is the result of a continuous remodeling process, in which various components of the extracellular matrix 
(ECM), growth factors, proteases and cytokines interact in a complex mechanism. Moreover, a possible 
regression of fibrosis has been recently described in less advanced rodent and human liver fibrosis models, 
due to the extraordinary capacity of liver cells to regenerate. But, chronic damage frequently leads to scar 
tissue and cirrhosis, greatly reducing the potential reversibility of fibrosis. In this view, the early 
identification of initial fibrosis and possible treatments represent the urgent goal of research in hepatology. 
Therefore, one of main fields of research in the last few years has been the elucidation of mechanisms of 
fibrosis in order to identify molecular targets permitting to revert liver fibrosis.  
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Assessment of fibrosis is another field of interest, because transaminases and liver function parameters do 
not correlate with fibrosis and fibrogenesis. Liver biopsy remains the gold standard to detect and assess the 
staging of fibrosis, but its invasivity, costs and the possibility of sample error, make it, mainly in the 
pediatric setting, an “imperfect test”. More than 2000 studies aiming to assess serological markers or 
imaging techniques to detect fibrosis have been published in the last five years. The combination of 
serological markers and elastography techniques seems to increase the diagnostic accuracy, but none of the 
currently available tests replaced liver biopsy.  
In the pathogenetic scenario, the role of gut-liver axis has emerged, opening interesting research fields in 
understanding the onset and progression of liver diseases, mainly in sclerosing cholangitis and NAFLD, and 
of treatment modalities. In the near future the characterization and manipulation of intestinal microbiota will 
represent an attractive field for hepatologist researchers.   
Early diagnosis and effective treatment are, especially in children, the mainstay of research in chronic 
hepatopathies, in order to efficaciously treat liver diseases, reducing the need of liver transplantation in 
adults, ameliorating quality of life and reducing direct and indirect costs due to liver diseases.  
Several advances have also been made in the treatment of hepatic disorders, both metabolic and infectious 
diseases, with new therapeutic options, which have deeply changed the natural history of several disorders. 
In the future, definitive therapy, such as targeted enzyme replacement or gene therapy, may be available for 
certain metabolic disorders. 
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Key issues:  
 
 Identifying the presence of serious liver disease in a pediatric patient at the early stage is of cardinal 
importance, since it can allow, in many cases, the modification of the therapeutic approach and 
natural history of the disease.  
 The diagnosis of liver disease in children is often delayed; it is important to keep in mind the 
frequent absence of symptoms or the presence of not-specific signs for several liver diseases.   
 Understanding the pathogenetic mechanisms provides the basis for discovering potential early 
predictors of the disease, suitable noninvasive diagnostic tools and design novel specific treatments 
for pediatric liver disease. 
 Pediatric NAFLD is now considered an increasing public health issue; a large-scale screening in high 
risk populations, especially among the overweight pediatric patients, should be suggested.  
 Chronic viral hepatitis (HBV or HCV) are mild diseases but can lead to cirrhosis and HCC in few 
cases during life.  
 With prompt immunosuppressive therapy the prognosis of patients affected by AIH is generally 
good, with symptom-free long-term survival in the majority of cases.  
 
 
 
  
 
 
 
D
ow
nl
oa
de
d 
by
 [A
nd
rea
 V
an
ia]
 at
 14
:36
 06
 D
ec
em
be
r 2
01
5 
References 
1. Arya G, Balistreri WF. Pediatric liver disease in United States: Epidemiology and impact. J 
Gastoenterol Hepatol 2002;17:521-525.  
2. Blachier M, Leleu H, Peck-Radosavljevic M, Valla D, Roudot-Thoraval F. The burden of liver 
disease in Europe: A review of available epidemiological data. J Hepatol 2013;58:593-608.  
3. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, et al. Global and 
regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic 
analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2095-2128. 
4. Dezsőfi A, Baumann U, Dhawan A, Durmaz O, Fischler B, Hadzic N, Hierro L, Lacaille F, McLin 
VA, Nobili V, Socha P, Vajro P, Knisely AS. Liver biopsy in children: position paper of the 
ESPGHAN Hepatology Committee. J Pediatr Gastroenterol Nutr 2015;60:408-20. 
* This position paper shows the role of liver biopsy in children, reporting the indications, 
contraindications  and type of procedures in principal pediatric hepatopathies. 
5. Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in 
children and adolescents. Pediatrics 2006; 118:1388-1393. 
6. Peverill W, Powell LW, Skoien R. Evolving concepts in the pathogenesis of NASH: beyond 
steatosis and inflammation. Int J Mol Sci. 2014;15:8591-638.  
7. Miele L, Valenza V, La Torre G, et al. Increased intestinal permeability and tight junction alterations 
in nonalcoholic fatty liver disease. Hepatology 2009;49:1877-87. 
8. Alisi A, Cianfarani S, Manco M, Agostoni C, Nobili V. Non-alcoholic fatty liver disease and 
metabolic syndrome in adolescents: pathogenetic role of genetic background and intrauterine 
environment. Ann Med 2012; 44:29-40. 
9. Marzuillo P, Grandone A, Perrone L, Miraglia del Giudice E. Understanding the pathophysiological 
mechanisms in the pediatric non-alcoholic fatty liver disease: The role of genetics. World J Hepatol. 
2015 Jun 18; 7(11): 1439–1443.  
10. Dongiovanni P, Anstee QM, Valenti L. Genetic Predisposition in NAFLD and NASH: Impact on 
Severity of Liver Disease and Response to Treatment. Curr Pharm Des 2013;19:5219-38. 
D
ow
nl
oa
de
d 
by
 [A
nd
rea
 V
an
ia]
 at
 14
:36
 06
 D
ec
em
be
r 2
01
5 
11. Nobili V, Donati B, Panera N, et al. A Four-Polymorphisms Risk Score Predicts Steatohepatitis in 
Children With Non-Alcoholic Fatty Liver Disease. J Pediatr Gastroenterol Nutr 2013 Dec 16. [Epub 
ahead of print]. 
12. Vajro P, Lenta S, Socha P, et al. Diagnosis of nonalcoholic fatty liver disease in children and 
adolescents: position paper of the ESPGHAN Hepatology Committee. J Pediatr Gastroenterol Nutr. 
2012;54:700-13. 
13. Marzuillo P, Grandone A, Perrone L, Miraglia del Giudice E. Controversy in the diagnosis of 
pediatric non-alcoholic fatty liver disease. World J Gastroenterol. 2015; 21: 6444–6450. 
14. Mansoor S, Collyer E, Alkhouri N. A comprehensive review of noninvasive liver fibrosis tests in 
pediatric nonalcoholic Fatty liver disease. Curr Gastroenterol Rep. 2015;17(6):23. 
15. Nobili, V. et al. Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis 
in pediatric nonalcoholic steatohepatitis. Hepatology 2008; 48: 442–448. 
16. Della Corte C, Liccardo D, Ferrari F, Alisi A, Nobili V. Current pharmacotherapy for treating 
pediatric nonalcoholic fatty liver disease. Expert Opin Pharmacother 2014 ;15:2501-11. 
* this review is an interesting overview of etiopathogenisis, diagnosis and treatment of NFLD in 
children 
17. Sanyal A, Chalasani N, Kowdley KV, et al. Pioglitazone, Vitamin E, or Placebo for Nonalcoholic 
Steatohepatitis. N Engl J Med. 2010; 362: 1675–1685.   
18. Chalasani N, Younossi Z, Lavine JE, et al; American Gastroenterological Association; American 
Association for the Study of Liver Diseases; American College of Gastroenterology. The diagnosis 
and management of non-alcoholic fatty liver disease: practice guideline by the American 
Gastroenterological Association, American Association for the Study of Liver Diseases, and 
American College of Gastroenterology. Gastroenterology 2012;142:1592-609. 
19. Lavine JE, Schwimmer JB, Van Natta ML, et al. Effect of vitamin E or metformin for treatment of 
nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. 
JAMA 2011;305:1659-68. 
D
ow
nl
oa
de
d 
by
 [A
nd
rea
 V
an
ia]
 at
 14
:36
 06
 D
ec
em
be
r 2
01
5 
20. Sarkhy AA, Al-Hussaini AA, Nobili V. Does vitamin E improve the outcomes of pediatric 
nonalcoholic fatty liver disease? A systematic review and meta-analysis. Saudi J Gastroenterol 
2014;20:143-53. 
21. Nobili V, Bedogni G, Alisi A, Pietrobattista A, Risé P, Galli C, Agostoni C. Docosahexaenoic acid 
supplementation decreases liver fat content in children with non-alcholic fatty liver disease: double 
blind randomized controlled clinical trial. Arch Child 2011; 96:350-353.  
22. Nobili V, Alisi A, Della Corte C, et al. Docosahexaenoic acid for the treatment of fatty liver: 
randomised controlled trial in children. Nutr Metab Cardiovasc Dis 2013;23:1066-70. 
23. Nobili V, Carpino G, Alisi A, De Vito R, Franchitto A, Alpini G, Onori P, Gaudio E. Role of 
docosahexaenoic acid treatment in improving liver histology in pediatric nonalcoholic fatty liver 
disease. PloS One 2014; 9:e88005. 
24. Pacifico L, Giansanti S, Gallozzi A, Chiesa C. Long chain omega-3 polyunsaturated fatty acids in 
pediatric metabolic syndrome. Mini Rev Med Chem. 2014;14(10):791-804. 
25. Janczyk W, Socha P, Wierzbicka-Rucińska A, et al. Omega-3 Fatty acids therapy in children with 
nonalcoholic Fatty liver disease: a randomized controlled trial. J Pediatr. 2015 Jun;166(6):1358-
63.e1-3.  
26. Schilling PL, Davis MM, Albanese CT, et al. National trends in adolescent bariatric surgical 
procedures and implications for surgical centers of excellence. J Am Coll Surg 2008;206:1–12 
27. Nobili V, Vajro P, Dezsofi A, Fischler B, Hadzic N, Jahnel J, Lamireau T, McKiernan P, McLin V, 
Socha P, Tizzard S, Baumann U. Indications and limitations of bariatric intervention in severely 
obese children and adolescents with and without nonalcoholic steatohepatitis: ESPGHAN 
Hepatology Committee Position Statement. J Pediatr Gastroenterol Nutr 2015;60:550-61. 
* It is the first position paper on the use of bariatric surgery in adolescents. Shows the  types of 
interventions used, to date, in the obese adolescents and gives the first indications for the 
execution of different types of interventions. 
28. Mummadi RR, Kasturi KS, Chennareddygair S, et al. Effect of bariatric surgery on nonalcoholic 
fatty liver disease: systematic review and metaanalysis. Clin Gastroenterol Hepatol 2008;6:1396–
402. 
D
ow
nl
oa
de
d 
by
 [A
nd
rea
 V
an
ia]
 at
 14
:36
 06
 D
ec
em
be
r 2
01
5 
29. Hofmann B. Bariatric surgery for obese children and adolescents: a review of the moral challenges. 
BMC Med Ethics. 2013;14:18.  
30. Nobili V, Corte CD, Liccardo D et al. Obalon intragastric balloon in the treatment of paediatric 
obesity: a pilot study. Pediatr Obes 2014[Epub ahead of print]. 
 
31. World Health Organization. Media Centre, Hepatitis B. WHO Website [cited 02.01.2013]. 
http://www.who.int/mediacentre/factsheets/fs204/en/index.html.  
32. Lavanchy D. Hepatitis B. Virus epidemiology, disease burden, treatment, and current and emerging 
prevention and control measures. J Viral Hepat 2004; 11: 97-107.  
33. Luo Z, Li L, Ruan B. Impact of the implementation of a vaccination strategy on hepatitis B virus 
infections in China over a 20-year period. Int J Infect Dis 2012; 16: e82-88.  
34. Liang X, Bi S, Yang W, et al. Epidemiological serosurvey of hepatitis B in China--declining HBV 
prevalence due to hepatitis B vaccination. Vaccine 2009; 27: 6550-57. 
35. Ni YH, Chang MH, Wu JF, Hsu HY, Chen HL, Chen DS. Minimization of hepatitis B infection by a 
25-year universal vaccination program. J Hepatol 2012; 57: 730-35. 
36. Chen SM, Kung CM, Yang WJ, Wang HL. Efficacy of the nationwide hepatitis B infant vaccination 
program in Taiwan. J Clin Virol 2011;52: 11-16. 
37. Romano' L, Paladini S, Van Damme P, Zanetti AR. The worldwide impact of vaccination on the 
control and protection of viral hepatitis B. Dig Liver Dis 2011; 43: S2-S7. 
** This review shows the data, to 2011, the efficacy of the vaccine for hepatitis B worldwide. The 
implementation of such vaccination programs led globally in a marked decrease in the disease, the 
rate of carrier and in hepatitis B-related morbidity and mortality. 
38. Chang M, Hsu H, Hsu H, Ni Y, Chen J, Chen D. The significance of spontaneous hepatitis B e 
antigen seroconversion in childhood: with special emphasis on the clearance of hepatitis B e antigen 
before 3 years of age. Hepatology 1995;22:1387–1392. 
39. Chang MH. Prevention of hepatocellular carcinoma by universal vaccination against hepatitis B 
virus: the effect and problems. Clin Cancer Res 2005;11:7953–7957. 
D
ow
nl
oa
de
d 
by
 [A
nd
rea
 V
an
ia]
 at
 14
:36
 06
 D
ec
em
be
r 2
01
5 
40. Yu MW, Chang HC, Liaw YF, Lin SM, Lee SD, Liu CJ, et al. Familial risk of hepatocellular 
carcinoma among chronic hepatitis B carriers and their relatives. J Natl Cancer Inst 2000;92:1159–
1164. 
41. Luo Z, Li L, Ruan B. Impact of the implementation of a vaccination strategy on hepatitis B virus 
infections in China over a 20-year period. Int J Infect Dis 2012;16:e82–e88. 
42. Della Corte C, Nobili V, Comparcola D, Cainelli F, Vento S. Management of chronic hepatitis B in 
children: an unresolved issue. J Gastroenterol Hepatol 2014;29:912-9. 
43. Sokal EM, Paganelli M, Wirth S, Socha P, Vajro P, Lacaille F, et al. Management of chronic 
hepatitis B in childhood: ESPGHAN clinical practice guidelines: consensus of an expert panel on 
behalf of the European Society of Pediatric Gastroenterology, Hepatology and Nutrition 2013; 
59:814-29. 
44. Paganelli M, Stephenne X, Sokal E. Chronic hepatitis B in children and adolescents. J Hepatol 2012; 
57: 885-96.  
45. Murray KF, Szenborn L, Wysocki J, et al. Randomized, placebo-controlled trial of tenofovir 
disoproxil fumarate in adolescents with chronic hepatitis B. Hepatology 2012; 56: 2018-26. 
46. Chen HL, Lee CN, Chang CH, et al; Taiwan Study Group for the Prevention of Mother-to-Infant 
Transmission of HBV (PreMIT Study); Taiwan Study Group for the Prevention of Mother-to-Infant 
Transmission of HBV PreMIT Study. Efficacy of maternal tenofovir disoproxil fumarate in 
interrupting mother-to-infant transmission of hepatitis B virus. Hepatology 2015;62:375-86. 
47. Greenup AJ, Tan PK, Nguyen V, et al. Efficacy and safety of tenofovir disoproxil fumarate in 
pregnancy to prevent perinatal transmission of hepatitis B virus. J Hepatol 2014;61:502-7. 
48. Lavanchy D. The global burden of hepatitis C. Liver Int 2009; 29: 74-81.  
49. Mack CL, Gonzalez-Peralta RP, Gupta N, Leung D, Narkewicz MR, Roberts EA, Rosenthal P, 
Schwarz KB; North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. 
NASPGHAN practice guidelines: Diagnosis and management of hepatitis C infection in infants, 
children, and adolescents. J Pediatr Gastroenterol Nutr. 2012;54:838-55. 
50. Bortolotti F, Verucchi G, Camma C, et al. Long-term course of chronic hepatitis C in children: from 
viral clearance to end-stage liver disease. Gastroenterology 2008;134:1900–7. 
D
ow
nl
oa
de
d 
by
 [A
nd
rea
 V
an
ia]
 at
 14
:36
 06
 D
ec
em
be
r 2
01
5 
51. European Association for Study of Liver. EASL Clinical Practice Guidelines: management of 
hepatitis C virus infection. J Hepatol. 2014;60:392-420. 
52. Tsubota A, Fujise K, Namiki Y, Tada N. Peginterferon and ribavirin treatment for hepatitis C virus 
infection. World J Gastroenterol 2011; 17: 419-432.  
53. Liang TJ, Ghany MG. Therapy of hepatitis C – back to the future. New Engl J Med 2014;370:2043-
7.  
* In this article are the first clinical and laboratory results on use of new drugs for the treatment of 
hepatitis C in adults (DAAs: direct-acting antiviral agents). 
54. Chang MH, Gordon LA, Fung HB. Boceprevir: a protease inhibitor for the treatment of hepatitis C. 
Clin Ther 2012; 34: 2021-2038 
55. Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, 
Goodman ZD, Boparai N, Di-Nubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP. 
Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206 
56. Serranti D, Indolfi G, Resti M. New treatments for chronic hepatitis C: an overview for 
paediatricians. World J Gastroenterol 2014; 20: 15965-15974.  
57. Herbst DA, Reddy KR. Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic 
hepatitis C virus infection. Expert Opin Investig Drugs 2013; 22: 527-536 
58. Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, Hindes RG, Berrey MM. 
Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013; 368: 
34-44.  
59. Brennan T, Shrank W. New expensive treatments for hepatitis C infection. JAMA 2014;312:593-4.  
60. Ala A, Walker AP, Ashkan K, Dooley JS, Schilsky ML. Wilson’sdisease. Lancet 2007;369:397—
408. 
61. Loudianos G, Gitlin JD. Wilson’s disease. Semin Liver Dis 2000;20:353—64. 
62. Dhawan A, Taylor RM, Cheeseman P, De Silva P, HatsiyiannakisL, Mieli-Vergani G. Wilson’s 
disease in children: 37-year expe-rience and revised King’s score for liver transplantation. Liver 
Transpl 2005;11:441—8. 
D
ow
nl
oa
de
d 
by
 [A
nd
rea
 V
an
ia]
 at
 14
:36
 06
 D
ec
em
be
r 2
01
5 
63. Ferenci P, Caca K, Loudianos G, Mieli-Vergani G, Tanner S, Sternlieb I, et al. Diagnosis and 
phenotypic classification of Wilson disease. Liver Int 2003;23:139-42. 
64. Nicastro E, Loudianos G, Zancan L, D’Antiga L, Maggiore G,Marcellini M, et al. Genotype-
phenotype correlation in Italianchildren with Wilson’s disease. J Hepatol 2009;50:555-61. 
65. El Balkhi S, Trocello JM, Poupon J, Chappuis P, Massicot F, Girardot-Tinant N, et al. Relative 
exchangeable copper: a new highly sensitive and highly specific biomarker for Wilson’s dis- ease 
diagnosis. Clin Chim Acta 2011;412:2254-60.  
66. Nicastro E, Ranucci G, Vajro P, Vegnente A, Iorio R. Re-evaluation of the diagnostic criteria for 
Wilson disease inchildren with mild liver disease. Hepatology 2010;52:1948-56. 
67. Roberts EA, Schilsky ML. American Association for Study of Liver Diseases (AASLD). Diagnosis 
and treatment of Wilson disease: an update. Hepatology 2008;47:2089-111. 
68. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Wilson’s 
disease. J Hepatol 2012;56:671—85.  
69. The Human Gene Mutation Database. http://www.hgmd.cf. ac.uk/ac/gene.php?gene=ATP7B.  
70. Schilsky ML. Long-term outcome for Wilson disease: 85% good. Clin Gastroenterol Hepatol 
2013;16:1542-3565. 
71. Mieli-Vergani G, Vergani D. Autoimmune hepatitis. Nat Rev Gastroenterol Hepatol 2011;8:320-9. 
72. Krawitt EL. Discrimination of autoimmune hepatitis: autoantibody typing and beyond. J 
Gastroenterol. 2011;46:39-41. 
73. Mieli-Vergani G, Vergani G. Autoimmune hepatitis. J Hepatol 2011;55:171-82 
74. Gregorio GV, Portmann B, Reid F, Donaldson PT, Doherty DG, McCartney M, et al. Autoimmune 
hepatitis in childhood: a 20-year experience. Hepatology 1997;25:541–7. 
75. Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, et al. Diagnosis and 
management of autoimmune hepatitis. Hepatology 2010;51:2193-213.  
76. Radhakrishnan KR, Alkhouri N, Worley S, Arrigain S, Hupertz V, Kay M, et al. Autoimmune 
hepatitis in children--impact of cirrhosis at presentation on natural history and long-term outcome. 
Dig Liver Dis 2010;42:724-8. 
77. Vergani D, Mieli-Vergani G. Pharmacological management of autoimmune hepatitis. N Engl J Med 
D
ow
nl
oa
de
d 
by
 [A
nd
rea
 V
an
ia]
 at
 14
:36
 06
 D
ec
em
be
r 2
01
5 
2006;354:54-66 
78. Aw MM, Dhawan A, Samyn M, Bargiota A, Mieli-Vergani G. Mycophenolate mofetil as rescue 
treatment for autoimmune liver disease in children: a 5-years follow up. J Hepatol 2009;51:156-60. 
79. Schramm C, Lohse AW. Role of mycophenolate mofetil in the treatment of autoimmune hepatitis. J 
Hepatol 2011;55:510-1.  
80. Tannous MM, Cheng J, Muniyappa K, Farooq I, Bharara A, Kappus M, et al. Use of tacrolimus in 
the treatment of autoimmune hepatitis: a single centre experience. Aliment Pharmacol Ther 
2011;34:405-7. 
81. Damoiseaux JC, van Breda Vriesman PJ. Cyclosporin A-induced autoimmunity: the result of 
defective de novo T-cell development. Folia Biol 1998;44:1-9. 
82. Wiegand J, Schuler A, Kanzler S, Lohse A, Beuers U, Kreisel W, et al. Budesonide in previously 
untreated autoimmune hepatitis. Liver Int 2005;25:927-34. 
83. Csepregi A, Rocken C, Treiber G, Malfertheiner P. Budesonide induces complete remission in 
autoimmune hepatitis. World J Gastroenterol 2006;12:1362-6. 
84. Woynarowski M, Nemeth A, Baruch Y, et al; European Autoimmune Hepatitis-Budesonide Study 
Group. Budesonide versus prednisone with azathioprine for the treatment of autoimmune hepatitis in 
children and adolescents. J Pediatr 2013;163:1347-53. 
85. Manns MP, Woynarowski M, Kreisel W, et al; European AIH-BUC-Study Group. Budesonide 
induces remission more effectively than prednisone in a controlled trial of patients with autoimmune 
hepatitis. Gastroenterology. 2010;139:1198-206. 
86. Floreani A, Liberal R, Vergani D, Mieli-Vergani G. Autoimmune hepatitis: Contrasts and 
comparisons in children and adults - a comprehensive review. J Autoimmun. 2013 Oct;46:7-16. 
87. Gassert DJ, Tanaka HGK, Reinus JF. Corticosteroid-Responsive Cryptogenic Chronic Hepatitis: 
Evidence for Seronegative Autoimmune Hepatitis. Dig Dis Sci 2007;52:2433–7. 
 
 
 
 
D
ow
nl
oa
de
d 
by
 [A
nd
rea
 V
an
ia]
 at
 14
:36
 06
 D
ec
em
be
r 2
01
5 
Financial and competing interests disclosure 
The authors have no relevant affiliations or financial involvement with any organization or entity with a 
financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This 
includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or 
patents received or pending, or royalties. 
 
Table 1. Most frequent cause of liver disease in children according to age group  
Infants Older children and adolescents 
 
Cholestatic disease NAFLD/NASH 
 Biliary Atresia Wilson disease 
Choledochal cyst AIH/SC 
Alagille syndrome Viral hepatitis 
    PFIC/BRIC Toxic (alcohol or drugs) 
Caroli disease Metabolic disease 
Cholelithiasis Cystic Fibrosis 
Idiopatic Neonatal Hepatitis Alpha-1-antitripsina deficiency 
Cystic Fibrosis Alagille syndrome 
Alpha-1-antitripsina deficiency BRIC/PFIC 
Hypothyroidism  
Neonatal iron storage disease  
Infection  
Metabolic disease  
Disorders of carbohydrate metabolism  
Peroxisomal disorders  
 Disorders of amino acids metabolism  
 Disorders of lipid metabolism  
Toxic injury   
Tumors  
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Table 2. Clinical and laboratory red flags to suspect a liver disease 
 
Signs Symptoms  
 
Hepatomegaly  
Hepatosplenomegaly 
Jaundice 
Gastrointestinal bleeding 
Facies with dysmorphic features   
Spider nevi 
Xanthomas 
Dark and foamy urine 
Acholic stool 
 
Non-specific symptoms, such as 
asthenia, abdominal pain, anorexia 
Vomiting 
Pruritus 
Laboratory abnormalities 
Hypertransaminasemia 
Hyperbilirubinemia 
Hyper-GGT  
Hypoglycemia 
Hypergammaglobulinemia 
Hypoalbuminemia 
Abnormal coagulation indices  
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